The development of pharmacodynamic endpoint models for evaluation of therapeutics in pancreatic cancer

Amanda F. Baker, Tomislav Dragovich

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The lack of development of new, more effective, therapies for pancreatic cancer has been disappointing. Among the factors limiting the development of targeted therapy approaches has been the inherent molecular heterogeneity of this disease combined with the challenge of obtaining fresh tumor tissue for the identification of pharmacodynamic biomarkers to segment patients based on target expression and resistance factors. Although many pre-clinical studies include pharmacodynamic studies, few large clinical studies have included similar biological correlative endpoints. Gemcitabine, although only modestly effective, still remains the standard of care. Emerging studies have identified potential molecular and genetic markers for cellular transporters and metabolism of gemcitabine which may be useful in predicting both clinical benefit and toxicity from this agent. The continued development of new therapeutics combined with identification of pharmacodynamic biomarkers to predict and monitor response to anti-cancer agents represents an exciting opportunity to individualize therapy and improve outcomes in this challenging disease.

Original languageEnglish (US)
Title of host publicationDrug Discovery in Pancreatic Cancer
Subtitle of host publicationModels and Techniques
PublisherSpringer New York
Pages271-289
Number of pages19
ISBN (Print)9781441911599
DOIs
StatePublished - Dec 1 2010

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'The development of pharmacodynamic endpoint models for evaluation of therapeutics in pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Baker, A. F., & Dragovich, T. (2010). The development of pharmacodynamic endpoint models for evaluation of therapeutics in pancreatic cancer. In Drug Discovery in Pancreatic Cancer: Models and Techniques (pp. 271-289). Springer New York. https://doi.org/10.1007/978-1-4419-1160-5_14